14 analysts' median target is $106[FMP target], stock is $102, +3.8% upside potential. After Q1 +17.9% EPS beat[FMP earnings], the stock moved +0.6%.
B+ = MoonshotScore 46[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].
Q4 consensus: revenue $100.2B[FMP est], EPS $1.86[FMP est]. 6 consecutive quarters of beat[FMP earnings].
Q1 EPS +17.9% beat[FMP] but the stock +0.6% D+1[FMP D+1]. Brian Newman promised $849.0M CapEx + a sequential decline in Q4 during the Q1 earnings call[Brian Newman capex transcript].
Watchlist
Fy26 Eps Guidance Increase
fy26_eps_guidance_increase
CVS Health raised its full year 2026 adjusted earnings per share (EPS) guidance to a range of $7.30 to $7.50 following strong first-quarter performance.
"Our strong first quarter performance gave us the confidence to increase our full year 2026 adjusted earnings per share guidance to a range of $7.30 to $7.50, up from the previous range of $7 to $7.20."
- David Joyner, Chair and Chief Executive Officer - Q1 FY26 Earnings Call - May 7, 2026
Cash Flow Leverage
cash_flow_leverage
CVS Health generated $4.2 billion in cash flow from operations in the first quarter and improved its leverage ratio to 3.84x, demonstrating strong financial health and capacity to return value to shareholders.
"In the first quarter, we generated cash flows from operations of approximately $4.2 billion and returned nearly $850 million to our shareholders through our quarterly dividend. Our leverage ratio at the end of the first quarter improved to 3.84x."
- Brian Newman, Chief Financial Officer - Q1 FY26 Earnings Call - May 7, 2026
Aetna Margin Recovery
aetna_margin_recovery
Aetna achieved over $1 billion of year-over-year adjusted operating income improvement in the first quarter due to successful execution of its margin recovery plans.
"We drove over $1 billion of year-over-year AOI improvement at Aetna."
- Brian Newman, Chief Financial Officer - Q1 FY26 Earnings Call - May 7, 2026
Prior Authorization Efficiency
prior_authorization_efficiency
Aetna leads in operational efficiency by having the fewest medical services subject to prior authorization in the industry, approving over 95% of eligible prior authorizations within 24 hours, with over 80% approved in real time.
"Aetna has the fewest medical services subject to prior authorization in the industry. Our focus on embedding technology within each of our businesses has enabled us to approve more than 95% of the eligible prior authorizations within 24 hours, with over 80% being approved in real time."
- David Joyner, Chair and Chief Executive Officer - Q1 FY26 Earnings Call - May 7, 2026
Biosimilar Adoption Strategy
biosimilar_adoption_strategy
CVS Health will exclude branded STELARA from its commercial formularies starting July 1, 2026, replacing it with low-cost biosimilars, aiming to replicate the over 90% patient conversion success achieved with HUMIRA.
"We recently announced that on July 1, 2026, we will exclude branded STELARA from our commercial template formularies to be replaced with the low-cost, effective biosimilars. We'll use the same proven playbook that allowed us to be the only ones to meaningfully move share with HUMIRA, converting over 90% of eligible patients."
- David Joyner, Chair and Chief Executive Officer - Q1 FY26 Earnings Call - May 7, 2026
Stock Expert AI - Methodology
9-pillar methodology. Cash Runway and Price Momentum strong. Revenue Growth weak.
How is it calculated? ->6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).
How is it calculated? ->Quality business, trading at fair value.
How is it calculated? ->Past Performance
Q1 (May 7, 2026): EPS $2.57 vs $2.18 est[FMP], +17.9% beat. D+1 movement: +0.6%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.
Q1: EPS $2.57 vs $2.18 beat[FMP], stock +0.6% D+1[FMP].
No RPO/backlog concentration disclosed in Q1 earnings call.
Q1 CapEx $849.0M[FMP cashflow]. Q1 op margin 4.7%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $1.86[FMP], CapEx threshold "below $849.0M"[Brian Newman]. Two anchors, three scenarios.
Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This CVS (CVS) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.